M Dama1, J Shah2, R Norman3, S Iyer2, R Joober2, N Schmitz2, A Abdel-Baki4, A Malla2. 1. Prevention and Early Intervention Program for Psychosis (PEPP-Montreal), Douglas Mental Health University Institute, Montreal, QC, Canada. 2. Department of Psychiatry, McGill University, Montreal, QC, Canada. 3. Departments of Psychiatry and Epidemiology & Biostatistics, Western University, London, ON, Canada. 4. Department of Psychiatry, Universite de Montreal, Montreal, QC, Canada.
Abstract
OBJECTIVE: To test whether duration of untreated psychosis (DUP) < 3 months, recommended by the World Health Organization/International Early Psychosis Association, enhances the effects of an extended early intervention service (EEIS) on symptom remission. METHOD: We examined data from a randomized controlled trial in which patients who received 2 years of treatment in EIS for psychosis were subsequently randomized to either 3 years of EEIS or 3 years of regular care (RC). Using a DUP cut-off ≤ 12 weeks (approximately < 3 months), patients were split into two groups. Length of positive, negative and total symptom remission were the outcomes. RESULTS:Patients (N = 217) were mostly male (68%) with schizophrenia spectrum disorder (65%); 108 (50%) received EEIS (58 had DUP ≤12 weeks; 50 had DUP >12 weeks). Interaction between treatment condition (EEIS vs. RC) and DUP cut-off ≤ 12 weeks was only significant in multiple linear regression model examining length of negative symptom remission as the outcome (adjusted β = 36.88 [SE = 15.88], t = 2.32, P = 0.02). EEIS patients with DUP ≤12 weeks achieved 25 more weeks of negative symptom remission than EEIS patients with DUP >12 weeks. CONCLUSION: Having a short DUP may be critical in deriving long-term benefits from EIS for psychosis, including EEIS settings. This work empirically supports policy recommendations of reducing DUP <3 months.
RCT Entities:
OBJECTIVE: To test whether duration of untreated psychosis (DUP) < 3 months, recommended by the World Health Organization/International Early Psychosis Association, enhances the effects of an extended early intervention service (EEIS) on symptom remission. METHOD: We examined data from a randomized controlled trial in which patients who received 2 years of treatment in EIS for psychosis were subsequently randomized to either 3 years of EEIS or 3 years of regular care (RC). Using a DUP cut-off ≤ 12 weeks (approximately < 3 months), patients were split into two groups. Length of positive, negative and total symptom remission were the outcomes. RESULTS:Patients (N = 217) were mostly male (68%) with schizophrenia spectrum disorder (65%); 108 (50%) received EEIS (58 had DUP ≤12 weeks; 50 had DUP >12 weeks). Interaction between treatment condition (EEIS vs. RC) and DUP cut-off ≤ 12 weeks was only significant in multiple linear regression model examining length of negative symptom remission as the outcome (adjusted β = 36.88 [SE = 15.88], t = 2.32, P = 0.02). EEIS patients with DUP ≤12 weeks achieved 25 more weeks of negative symptom remission than EEIS patients with DUP >12 weeks. CONCLUSION: Having a short DUP may be critical in deriving long-term benefits from EIS for psychosis, including EEIS settings. This work empirically supports policy recommendations of reducing DUP <3 months.
Authors: Delbert G Robinson; Nina R Schooler; Patricia Marcy; Robert D Gibbons; C Hendricks Brown; Majnu John; Kim T Mueser; David L Penn; Robert A Rosenheck; Jean Addington; Mary F Brunette; Christoph U Correll; Sue E Estroff; Piper S Mayer-Kalos; Jennifer D Gottlieb; Shirley M Glynn; David W Lynde; Susan Gingerich; Ronny Pipes; Alexander L Miller; Joanne B Severe; John M Kane Journal: Schizophr Bull Date: 2022-09-01 Impact factor: 7.348
Authors: Michael Groff; Eric Latimer; Ridha Joober; Srividya N Iyer; Norbert Schmitz; Sherezad Abadi; Amal Abdel-Baki; Nicola Casacalenda; Howard C Margolese; G Eric Jarvis; Ashok Malla Journal: Schizophr Bull Date: 2021-03-16 Impact factor: 9.306
Authors: Alison R Yung; Stephen J Wood; Ashok Malla; Barnaby Nelson; Patrick McGorry; Jai Shah Journal: Psychol Med Date: 2019-10-28 Impact factor: 7.723